2021 Fiscal Year Annual Research Report
Development of a lymphatic drug delivery system to treat very early metastatic lymph nodes
| Project/Area Number |
20K20161
|
|---|
| Research Institution | Tohoku University |
|---|
Principal Investigator |
|
|---|
| Project Period (FY) |
2020-04-01 – 2022-03-31
|
| Keywords | lymph node / metastasis / cancer / DDS / lymphatic delivery |
|---|
| Outline of Annual Research Achievements |
LDDS is assumed to be capable of treating and preventing clinical N0 and downstream lymph nodes by filling the inside of clinical N0 lymph nodes with drugs and delivering the drug to downstream lymph nodes. In this year's study, the anti-tumor effect of LDDS on N0 metastatic lymph nodes was examined using the anti-cancer drug docetaxel dissolved in a solvent of appropriate osmolarity and viscosity obtained in the previous year, and MXH10/Mo/lpr mice were used. Tumor cells were transplanted into the subiliac lymph node (SiLN) and induced metastasis in the proper axillary lymph node (PALN); SiLN was defined as the N0 lymph node and PALN as a metastatic downstream lymph node. Docetaxel with adjusted osmolality (700-3,000 kPa) and viscosity (< 40 mPas) was administered to SiLNs; tumor growth in SiLNs and PALNs was suppressed. We anticipate these optimal ranges to be a starting point for developing more effective drug regimens to treat metastatic LN with the LDDS.
|
